Table 1 Demographic and clinical characteristics of the participants at baseline
Variables | Pemafibrate (n = 152) | Control (n = 141) | P-value |
|---|---|---|---|
Age | 60.9 ± 11.8 | 61.4 ± 11.5 | 0.723 |
Female sex (n, (%)) | 53 (34.9) | 57 (40.4) | 0.326 |
Duration of diabetes (n, (%)) | 0.430 | ||
<5 years | 31 (20.4) | 34 (24.1) | |
>5–15 years | 64 (42.1) | 64 (45.4) | |
>15 years | 57 (37.5) | 43 (30.5) | |
Body mass index (kg/m2) | 27.9 ± 3.9 | 28.1 ± 4.3 | 0.777 |
HbA1c (%) | 7.04 ± 0.78 | 7.03 ± 0.81 | 0.952 |
AST (U/L) | 31.1 ± 17.3 | 29.0 ± 14.8 | 0.260 |
ALT (U/L) | 29 (20, 44) | 30 (19, 39) | 0.531 |
ALT ≤ ULN (U/L) | 18 (15, 25) | 17 (14, 22) | 0.408 |
ULN < ALT ≤ 2× ULN (U/L) | 36 (30, 43) | 35 (30, 39) | 0.389 |
2× ULN < ALT (U/L) | 65 (56, 83) | 63 (44, 79) | 0.372 |
γ-GTP (U/L) | 41 (25, 72) | 44 (30, 60) | 0.776 |
eGFR (mL/min/1.73m2) | 69.3 ± 18.9 | 69.4 ± 23.0 | 0.963 |
Triglyceride (mg/dL) | 186 (145, 214) | 185 (155, 230) | 0.819 |
HDL-C (mg/dL) | 51.5 ± 12.8 | 50.7 ± 11.9 | 0.588 |
LDL-C (mg/dL) | 100.9 ± 25.7 | 105.3 ± 31.0 | 0.191 |
Hypertension (n, (%)) | 98 (64.5) | 91 (64.5) | 0.991 |
Cardiovascular diseases (n, (%)) | 13 (8.6) | 9 (6.4) | 0.481 |
Fibrate use (n, (%)) | 53 (34.9) | 37 (26.2) | 0.110 |